These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15068492)

  • 1. Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy.
    Cundy T; Wheadon L; King A
    J Bone Miner Res; 2004 May; 19(5):703-11. PubMed ID: 15068492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic idiopathic hyperphosphatasia: normalization of bone turnover with cyclical intravenous pamidronate therapy.
    Tau C; Mautalen C; Casco C; Alvarez V; Rubinstein M
    Bone; 2004 Jul; 35(1):210-6. PubMed ID: 15207759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early identification of a 12-bp tandem duplication in TNFRSF11A encoding receptor activator of nuclear factor-kappa B (RANK): Clinical characterization and response to bisphosphonate therapy.
    Craven M; Vajravelu ME; Shekdar KV; Levine MA; Mumm S; Whyte MP; Mancilla EE
    Bone; 2023 May; 170():116698. PubMed ID: 36740137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
    J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
    Papapoulos SE; Frölich M
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic strategy in Paget's disease of bone.
    Meunier PJ; Vignot E
    Bone; 1995 Nov; 17(5 Suppl):489S-491S. PubMed ID: 8573424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
    Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
    J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial.
    Reid IR; Nicholson GC; Weinstein RS; Hosking DJ; Cundy T; Kotowicz MA; Murphy WA; Yeap S; Dufresne S; Lombardi A; Musliner TA; Thompson DE; Yates AJ
    Am J Med; 1996 Oct; 101(4):341-8. PubMed ID: 8873503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term intravenous therapy with Neridronate in Paget's disease.
    Adami S; Bevilacqua M; Broggini M; Filipponi P; Ortolani S; Palummeri E; Ulivieri F; Nannipieri F; Braga V
    Clin Exp Rheumatol; 2002; 20(1):55-8. PubMed ID: 11892710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
    Chapurlat RD; Delmas PD; Liens D; Meunier PJ
    J Bone Miner Res; 1997 Oct; 12(10):1746-52. PubMed ID: 9333137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease.
    Grasemann C; Schündeln MM; Hövel M; Schweiger B; Bergmann C; Herrmann R; Wieczorek D; Zabel B; Wieland R; Hauffa BP
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3121-6. PubMed ID: 23788687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate.
    Filipponi P; Cristallini S; Policani G; Casciari C; Gregorio F
    Bone; 1998 Dec; 23(6):543-8. PubMed ID: 9855463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Paget's disease: case report].
    Wegierska M; Ignaczak P; Zalewska J; Jeka S
    Ann Acad Med Stetin; 2011; 57(3):64-9; discussion 69. PubMed ID: 23383549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and biochemical response of TNFRSF11A-mediated early-onset familial Paget disease to bisphosphonate therapy.
    Riches PL; Imanishi Y; Nakatsuka K; Ralston SH
    Calcif Tissue Int; 2008 Oct; 83(4):272-5. PubMed ID: 18836673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.